SonoThera Raises $61 Million To Advance Ultrasound-Guided, Nonviral Gene Therapy Platform
December 5, 2022
Gene therapy biotech SonoThera said it has completed a $61 million series A financing round that will support the continued development of its ultrasound-guided, nonviral, gene therapy platform and treatments, designed to provide patients with genetic medicines.
Lead investor ARCH Venture Partners was joined by investors Illumina Ventures, Johnson & Johnson Innovation – JJDC, Vertex Ventures, and Medical Excellence Capital. Eli Lilly & Company, Alexandria Venture Investments, Lifespan Investments, Formic Ventures, Foothill Ventures, and Wilson Sonsini also participated in the financing.
“The significant support of our investors further enables our preclinical development and early manufacturing activities while in parallel, we strategically build our team,” said Kenneth Greenberg, co-founder and CEO of SonoThera. “Each step brings us closer to one day making our nonviral gene therapies a reality for patients and providers.”
SonoThera’s ultrasound-guided platform uses sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads of diverse formats and sizes, selectively targeting a wide range of organs within the body. Unlike traditional gene therapies, the technology does not require viral vectors which can be immunogenic and lead to both safety and efficacy challenges.
“We believe in the innovation SonoThera is developing to provide a new generation of genetic medicines and are pleased to contribute to its success,” said Steven Gillis of ARCH Venture Partners. “The concept of a targeted, non-invasive, nonviral therapy which could deliver a variety of payloads would significantly change the genetic treatment paradigm for patients, potentially across a variety of disease states.”
Author: Rare Daily Staff
Sign up for updates straight to your inbox.